Journal article
Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells
Oncology letters, Vol.2(1), pp.91-94
01/01/2011
DOI: 10.3892/ol.2010.198
PMCID: PMC3412472
PMID: 22870135
Abstract
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is an effective therapy for non-small cell lung cancer (NSCLC). However, resistance to erlotinib reduces its efficacy. To investigate the basis of erlotinib resistance, we isolated erlotinib-resistant human NSCLC A549 cells, termed A549/ER cells. The A549/ER cells were found to be resistant to erlotinib, as well as paclitaxel and gemcitabine. We then performed a PCR array to investigate the resistance to erlotinib in A549/ER cells. EGFR expression in A549/ER cells was decreased compared to A549 cells. The expression of fibroblast growth factor 2 (FGF2) and p21 in A549/ER was increased when compared to A549 cells. Our results suggest that the down-regulation of EGFR and up-regulation of FGF2 is related to resistance to erlotinib in A549/ER cells.
Details
- Title: Subtitle
- Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells
- Creators
- RYUJI Ikeda - Kagoshima UniversityLEE C Vermeulen - UW Health University HospitalELIM Lau - University of Wisconsin–MadisonZHISHENG Jiang - University of Wisconsin–MadisonSHANNON M Kavanaugh - University of Wisconsin Carbone Cancer CenterKATSUSHI Yamada - Kagoshima UniversityJILL M Kolesar - University of Wisconsin Carbone Cancer Center
- Resource Type
- Journal article
- Publication Details
- Oncology letters, Vol.2(1), pp.91-94
- Publisher
- D.A. Spandidos
- DOI
- 10.3892/ol.2010.198
- PMID
- 22870135
- PMCID
- PMC3412472
- ISSN
- 1792-1074
- eISSN
- 1792-1082
- Language
- English
- Date published
- 01/01/2011
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984695787702771
Metrics
4 Record Views